← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	4,698	+37	+0.8%	$457B
2	2 AbbVie ABBV $501B	4,234	+118	+3%	$335B
3	3 Merck MRK $364B	3,852	+42	+1%	$254B
4	4 Amgen AMGN $230B	3,164	+12	+0.4%	$162B
5	5 Pfizer PFE $166B	2,841	-122	-4%	$91.9B
6	6 Bristol-Myers Squibb BMY $121B	2,530	-14	-0.6%	$96.7B
7	7 Gilead Sciences GILD $190B	2,291	-40	-2%	$141B
8	8 Novartis NVS $279B	1,625	+21	+1%	$21.3B
9	9 AstraZeneca AZN $251B	1,507	+122	+9%	$196B
10	10 Regeneron Pharmaceuticals REGN $80.1B	1,340	-60	-4%	$57.1B
11	11 GSK GSK $95.9B	1,045	+7	+0.7%	$18.2B
12	12 Incyte INCY $22.6B	861	+46	+6%	$23B
13	13 Natera NTRA $56.9B	850	+83	+11%	$37.2B
14	14 Exelixis EXEL $15.1B	760	+59	+8%	$14.1B
15	15 Revolution Medicines RVMD $41.5B	694	+180	+35%	$40.1B
16	16 Halozyme HALO $13.3B	674	+37	+6%	$9.62B
17	17 Jazz Pharmaceuticals JAZZ $13.6B	647	+71	+12%	$15.5B
18	18 Guardant Health GH $21.9B	601	+115	+24%	$20B
19	19 Tempus AI TEM $12.4B	489	+62	+15%	$6.41B
20	20 Lantheus LNTH $6.53B	468	+60	+15%	$8.34B
21	21 ImmunityBio IBRX $10.5B	405	+19	+5%	$1.77B
22	22 Takeda Pharmaceutical TAK $60.7B	379	+17	+5%	$1.67B
23	23 Veracyte VCYT $3.5B	370	+36	+11%	$5.23B
24	24 Recursion Pharmaceuticals RXRX $2.01B	343	+8	+2%	$1.33B
25	25 Qiagen QGEN $9.41B	337	-9	-3%	$5.68B